Episode 330 - Zan Fleming - Founder and Executive Chairman of Kinexum

In this episode of the Diabetes Innovators Series, the conversation explores the evolution of diabetes treatment, the challenges faced in managing diabetes today, and the future of diabetes research. Zan, an endocrinologist and former FDA executive and Founder and executive chairman of Kinexum, shares insights from his career, including the historical context of diabetes management, the importance of A1C as a marker, and the potential of new treatments like GLP-1 agonists. The discussion also touches on the concept of meta-abesity, the shared root causes of chronic diseases, and the need for a focus on health span rather than just lifespan. Chapters 00:00 Introduction to Diabetes Innovation Series 03:06 Zan's Journey in Diabetes Research 06:05 Transforming Diabetes Treatment: A Historical Perspective 09:00 The Evolution of Diabetes Management Tools 11:42 Challenges in Diabetes Management Today 14:41 The Future of Diabetes Treatment: Aiming for a Cure 17:57 Understanding the Drug Approval Process 20:32 Meta-Abesity: A New Perspective on Chronic Diseases 23:48 Innovations in Longevity and Health Span 26:27 The Role of GLP-1 Agonists in Diabetes Management 29:29 Future Directions in Diabetes Research 32:29 Memorable Moments in Drug Proposals 35:37 Conclusion and Future Collaborations Resources: Kinexum Zan Fleming

There are no comments yet.

Please log in to write the first comment.